George Hanna, MD, Infectious Disease, Princeton, NJ

GeorgeJHannaMD

Infectious Disease Princeton, NJ

HIV/AIDS Medicine

Independent Biopharmaceutical Consultant with Expertise in Clinical Drug Development, Scientific and Medical Affairs, and Infectious Diseases

Dr. Hanna is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Hanna's full profile

Already have an account?

Education & Training

  • Massachusetts General Hospital
    Massachusetts General HospitalFellowship, Infectious Disease, 1996 - 2000
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1992 - 1995
  • Baylor College of Medicine
    Baylor College of MedicineClass of 1992

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2009 - 2021
  • IL State Medical License
    IL State Medical License 2005 - 2008
  • PA State Medical License
    PA State Medical License 2001 - 2022
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Infectious Disease

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • FDA Approves Expanded Indications for 2 HIV Therapies
    FDA Approves Expanded Indications for 2 HIV TherapiesSeptember 25, 2019 14:27
  • Merck’s Pifeltro (Doravirine) and Delstrigo (doravirine/lamivudine/tenofovir Disoproxil Fumarate) Receive FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically Suppressed
    Merck’s Pifeltro (Doravirine) and Delstrigo (doravirine/lamivudine/tenofovir Disoproxil Fumarate) Receive FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically SuppressedSeptember 24, 2019 04:51
  • Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019
    Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019July 24, 2019 22:55
  • Join now to see all

Grant Support

  • Selection Of Multidrug Resistant Hiv-1rtNational Institute Of Allergy And Infectious Diseases2001
  • Selection Of Multidrug Resistant Hiv-1rtNational Institute Of Allergy And Infectious Diseases1999–2001

Professional Memberships